With the increasing availability of a variety of antifungal agents, susceptibility testing of yeasts associated with significant infections is becoming increasingly important. Clinical laboratorians must know how to approach antifungal testing to help guide treatment decisions. This webinar will focus on the most current recommendations for antifungal testing and reporting to include those found in the newer CLSI documents M57 and M59. The use of Epidemiological cutoff values (ECVs) to interpret results will be described in detail as will effective reporting of antifungal susceptibility test results to the healthcare team. Newer antifungal agents including isavuconazole will be described and strategies for when to test specific agents will be presented. Finally, speakers will address applications in the clinical laboratory for the new CAP checklist items related to antifungal susceptibility testing and reporting. This webinar is intended for laboratorians, pharmacists and clinicians who perform antifungal testing and/or utilize results of antifungal testing for clinical decisions.
- Communicate the difference between a clinical breakpoint and an epidemiologic cutoff value (ECV) to the healthcare team.
- Formulate approaches to susceptibility testing and reporting of newly approved and older antifungal agents.
- Apply the recently published College of American Pathologists (CAP) antifungal checklist items to the clinical laboratory.
Mariana Castanheira, PhD JMI Laboratories
Audrey N. Schuetz, MD, MPH, D(ABMM) Mayo Clinic